top of page
Aug 23, 2022
Chemotherapy, radiotherapy and adverse drug reaction mitigation using NGS
Chemotherapy is often aggressive and can provoke severe toxicity and adverse drug reactions (ADR). Noticeable differences also exist in...
Aug 22, 2022
NGS testing for CYP gene and variation in drug responses
Among the most researched pharmacogenes is the CYP gene superfamily (Fukunaga et al., 2021), which influences drug-metabolising enzymes...
Aug 22, 2022
Oncology targeted therapy with egSEQ NGS
Personalised diagnostic and precision medicine for cancer patients involves tailoring each patient’s treatment based on the genomic...
Aug 22, 2022
Recurrence monitoring of colorectal and breast cancer patients with egSEQ Comprehensive Solid Tumour
With the continuous discovery of genetic targets correlated with recurrence risk, time to recurrence (TTC) and/or overall survival, it is...
bottom of page